Relay Therapeutics (RLAY) Total Liabilities: 2020-2025
Historic Total Liabilities for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $62.3 million.
- Relay Therapeutics' Total Liabilities fell 31.74% to $62.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 31.74%. This contributed to the annual value of $93.5 million for FY2024, which is 1.66% up from last year.
- Relay Therapeutics' Total Liabilities amounted to $62.3 million in Q3 2025, which was down 1.41% from $63.2 million recorded in Q2 2025.
- Relay Therapeutics' Total Liabilities' 5-year high stood at $168.9 million during Q3 2022, with a 5-year trough of $38.6 million in Q1 2021.
- Over the past 3 years, Relay Therapeutics' median Total Liabilities value was $92.0 million (recorded in 2023), while the average stood at $100.1 million.
- Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Total Liabilities was 202.81% (2021), while the steepest drop was 80.94% (2021).
- Quarterly analysis of 5 years shows Relay Therapeutics' Total Liabilities stood at $110.6 million in 2021, then spiked by 35.18% to $149.6 million in 2022, then crashed by 38.50% to $92.0 million in 2023, then climbed by 1.66% to $93.5 million in 2024, then crashed by 31.74% to $62.3 million in 2025.
- Its last three reported values are $62.3 million in Q3 2025, $63.2 million for Q2 2025, and $78.3 million during Q1 2025.